Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
Rp-3467 At Assigned Dose And Schedule, Olaparib 200-300 Mg Bid, Daily
Advanced Solid Tumor
Phase I
Active Not Recruiting
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
Aug 09, 2024
―
Rp-1664
Advanced Solid Tumor
Phase I
Active Not Recruiting
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Jan 09, 2024
―
Rp-6306 (Oral Pkmyt1 Inhibitor)
Adult Solid Tumor
Phase I
Terminated
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Nov 10, 2021
―
Rp-6306 (Oral Pkmyt1 Inhibitor)
Advanced Solid Tumor
Phase I
Terminated
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
Nov 03, 2021
―
Rp-6306, Rp-3500, Debio0123
Advanced Solid Tumor
Phase I
Recruiting
Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Apr 09, 2021
―
Talazoparib, Gemcitabine Injection, Rp-3500 (Camonsertib)
Advanced Solid Tumor
Phase I/II
Completed
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Jul 21, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Repare Therapeutics Inc (RPTX) have in its pipeline
RPTX is currently developing the following drugs: Rp-3467 At Assigned Dose And Schedule, Olaparib 200-300 Mg Bid, Daily, Rp-1664, Rp-6306 (Oral Pkmyt1 Inhibitor). These drug candidates are in various stages of clinical development as the company works toward FDA approval.